Trial Profile
Evaluation Of Efficiency Of Rituximab (MabThera) In the Adult Suffering from an Auto-Immune Thrombocytopenic Purpura Chronic And Severe And Candidate Splenectomy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Jun 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Therapeutic Use
- 03 Dec 2015 New trial record